Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has signed an agreement with an affiliated party to procure a production information system, aiming to enhance digital and intelligent management in the pharmaceutical industry [1][3]. Summary by Sections 1. Overview of the Related Transaction - The company’s wholly-owned subsidiary, Chengdu Shod Pharmaceutical Co., Ltd., plans to purchase a production information system from Beijing Qilijia Technology Co., Ltd. for a total amount of 2.2 million RMB, with a contract duration of three years [1][3][7]. 2. Basic Information of the Related Party - Beijing Qilijia Technology Co., Ltd. has a registered capital of 5 million RMB and was established on October 25, 2002. The company specializes in software development, technology consulting, and related services [2][5]. 3. Financial Data of the Related Party - As of June 30, 2025, Qilijia reported total assets of 1470.98 million RMB and total liabilities of 205.94 million RMB, with an owner's equity of 1265.04 million RMB. The company had a revenue of 392.14 million RMB in the first half of 2025 [5]. 4. Necessity and Impact of the Related Transaction - The transaction is essential for the company to implement digital and intelligent management in pharmaceutical production, aligning with the interests of the company and all shareholders. The pricing of the transaction is fair and does not harm the interests of minority shareholders [9][11]. 5. Approval Process for the Related Transaction - The independent directors and the board of supervisors have approved the transaction, confirming that it complies with the company's procurement management system and is based on fair market conditions [10][11].

经全体与会独立董事审议：本次关联交易是基于公司实施生产数字化智能管 理的实际业务而产生，主要目的是为了加快推进数字化、智能化在制药产业中融 合，实现药品生产数字化智能管理，符合公司和全体股东的利益，具有必要性。 本次交易严格按照公司采购管理制度及采购招标流程遴选供应商，按照公平、公 开、公正的原则从服务能力、解决方案、项目实施经验、项目团队能力等方面进 行综合全面考察，通过招投标流程比价，在符合商业惯例的前提下，从交易价格 谈判、付款方式及验收标准等方面保证上市公司利益，不会损害公司及股东特别 是中小股东的利益。我们同意将该关联交易事项提交公司第四届董事会第七次会 议审议，届时关联董事将回避表决。 表决结果：3 票同意、0 票反对、0 票弃权。 独立董事：李卫锋、程增江、方芳 成都苑东生物制药股份有限公司 第四届独立董事专门会议第三次会议决议 成都苑东生物制药股份有限公司（以下称"公司"）第四届独立董事专门会议 第三次会议通知于 2025 年 8 月 7 日以电话/微信等方式临时向全体独立董事发出， 会议于 2025 年 8 月 8 日以通讯表决方式召开。本次会议应出席独立董事 3 名， 实际出席独立董事 3 ...